The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment

Kaohsiung Medical University Chung-Ho Memorial Hospital70 enrolled

Overview

Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

Primary Objective: Use both listed and relatively safe drug, Silymarin, to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy. Patient Selection and Enrollment: Number of Subjects: Eligible patients will be randomized in 2 arms in the ratio of 1:1, to reach approximately 70 patients in total. Plan of the Study: Study Design This is an open-label, randomized, comparative, double arm, single center study to assess efficacy of Silymarin as adjuvant therapy on metastatic colorectal cancer patients undergoing FOLFIRI chemotherapy in Taiwan. Subject Number Eligible patients will be randomized in 2 arms in the ratio of 1:1, to reach approximately 70 patients in total. Study Schedule Study date: the time getting approval letter issued by both regulatory authority and institutional review board (IRB) Duration of study: From the date of the IRB was approved till the 70th patient was collected. Duration of Enrollment: From the date of the IRB was approved till the 70th patient was collected. Duration of treatment: From the 1st patient starting chemotherapy till the 70th patient finishing the 6th cycle chemotherapy. Duration of follow-up: From the 1st patient starting chemotherapy till 3 months after the 70th patient finishing the 6th cycle chemotherapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Colorectal Cancer

Interventions

SilymarinDRUG

During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The patient who is between 20 to 80 years old 2. The patient who is diagnosed metastatic colorectal cancer and received chemotherapy with FOLFIRI regimen 3. The female patient should not be pregnant or breast-feeding 4. The patient who has no severe co-morbidity, such as cardiovascular, cerebrovascular, malignant hypertension, renal and hepatobiliary disease. 5. The patient who has no associated drug allergy to this trial. 6. The patient who is in compliance with prescribed medication. 7. The patient who is willing to sign the permit of the clinical trial. Exclusion Criteria: 1. The patients who do not meet the main inclusion criteria or are not willing to sign the permit. 2. The patient who has viral hepatitis or carrier with impaired liver function.

Locations (1)

Chung-Ho Memorial Hospital, Kaohsiung Medical University:

Kaohsiung City, Taiwan

Outcomes

Primary Outcomes

GI associated adverse events

Response rate and grades of GI associated adverse events (AEs) according to the Response Evaluation Criteria in Solid Tumors (version 1.1)

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.